癌胚抗原（CEA）在无病乳腺癌患者随访中的应用

Carcinoembryonic antigen (CEA) in the follow-up of disease-free breast cancer patients.

作者信息

Veronesi A, Talamini R, Longhi S, Crivellari D, Galligioni E, Tirelli U, Trovò M G, Magri M D, Frustaci S, Figoli F, Zagonel V, Tumolo S, Grigoletto E

出版信息

Tumori. 1982 Dec 31;68(6):477-80. doi: 10.1177/030089168206800605.

DOI:10.1177/030089168206800605

PMID:7168012

Abstract

Carcinoembryonic antigen (CEA) assays (2536) were performed in 380 disease-free breast cancer patients after radical mastectomy. In the 334 evaluable patients with 3 or more determinations, the overall relapse rate after a median follow-up of 29 months was 11%. Of 203 patients with normal CEA values, 19 (9.3%) relapsed. In the 50 patients with the highest CEA value greater than 20 ng/ml, the relapse rate was 26%; in the 12 patients with gradually increasing CEA elevations it was 50%. However, CEA was unable to predict recurrence in N- patients. Premastectomy N+ was significantly associated with greater than 20 ng/ml or gradually increasing CEA values, suggesting the lack of an independent prognostic value of CEA in our patient population.

摘要

对380例接受根治性乳房切除术的无病乳腺癌患者进行了癌胚抗原（CEA）检测（2536次）。在334例可评估且进行了3次或更多次检测的患者中，中位随访29个月后的总体复发率为11%。在203例CEA值正常的患者中，19例（9.3%）复发。在50例CEA最高值大于20 ng/ml的患者中，复发率为26%；在12例CEA逐渐升高的患者中，复发率为50%。然而，CEA无法预测N-患者的复发情况。术前N+与CEA值大于20 ng/ml或逐渐升高显著相关，这表明在我们的患者群体中CEA缺乏独立的预后价值。